Cerus Corporation operates as a biomedical products company which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company was founded in 1991 and is based in Concord, California.
Cerus (CERS) announces study results that showed the complete inactivation of the SARS-CoV-2 virus in plasma components intended for transfusion via the use of its INTERCEPT Blood System, a device used by blood banks to reduce the risk of transfusion-transmitted infections from a range of pathogens in platelets, plasma and...
Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion. These data are consistent with prior INTERCEPT studies showing complete inactivation, to below the limit of detection, of other coronaviruses associated with severe pulmonary disease: MERS-CoV1,2 (2018, 2019) and SARS-CoV-13 (2005).
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]